Antibody Technologies and Platforms 2

• 4393 · PDF 开发一种在耐药肿瘤模型中具有高亲合力和强活性的抗CD171（L1CAM）抗体偶联药物 Development of an anti-CD171 (L1CAM) antibody-drug conjugate with high avidity and strong activity in resistant tumor models Kyoung-Ho Pyo, Hee Su Chae, Seong-Hyun Park, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Mi Jin Yoo, Min-Jung Shin, Hyo Jeong Hong, Jong-Soo Kang, Ju Hwan Kim, Seon-Joo Yoon, Taedong Han
• 4395 · PDF 一种同类最佳的HER2xHER2新型双互补位抗体偶联药物，采用高效、低毒设计以最大化抗体功能 A best-in-class HER2xHER2 novel biparatopic antibody-drug conjugate with an efficacious, low-toxicity design that maximizes antibody functionality Ge Song, Yushi Chi, Xiansong Xiong, Rui Liu, Xiaoling Yuan, Wan-Jen Yang, Wanli Zhang, Xinwei Wang, Boqi Gu, Qian Zou, Peng Huang, Kuichao Qu, Haixiang Yu, Futang Yang, Qingyu Wang, Chen Hu, Jijun Yuan
• 4396 · PDF K-679（一种超高DAR的EGFR靶向抗体载药单胶束偶联物[ADUC]）的选择性瘤内分布及T-DXd后活性 Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC) Hideo Yoshida, Hideyuki Higashi, Masato Mori, Kahori Hosono, Nobuhiro Fujimaki
• 4397 · PDF 利用患者来源类器官研究实体瘤背景下抗体偶联药物的旁观者效应 Leveraging patient-derived organoids to investigate bystander effects of antibody-drug conjugates in solid tumor backgrounds Oksana Sirenko, Nikki Carter
• 4398 · PDF 开发用于高通量抗体-药物偶联物癌症筛选的3D细胞模型 Developing 3D cell models for high-throughput antibody-drug conjugate screening in cancer Peilin Tian, Morgan Hamon, Sean Porazinski, Maria Kavallaris, Kristopher A. Kilian, Justin Gooding
• 4399 · PDF ANT045：一种新型抗体片段-药物偶联物（FDC）产品，用于治疗具有挑战性的cMET表达实体瘤 ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors Mahendra Deonarain, Bryan Edwards, Gokhan Yahioglu, Isabel Perez-Castro, Sam Ness, Anja Pomowski, Laura Bouché, Soraya Diez-Posada, Lowri Davies, Howard Desmond
• 4400 · PDF 降解剂抗体偶联物（DAC）作为一种下一代治疗方法，用于EGFR阳性癌症中选择性且强效的靶向蛋白降解 Degrader antibody conjugates (DACs) as a next-generation therapeutic approach for selective and potent targeted protein degradation in EGFR-positive cancers Jihye Lee, Soohyun Lee, Jiyoung Kim, Han Wool Kim, So Hyuk Kim, Onnuri Bae, Jeonghwa Han, Je Ho Ryu, Song Hee Lee
• 4401 · PDF 一种靶向实体瘤中碱性磷酸酶ALPP和ALPPL2的新型抗体-药物偶联物 A novel antibody-drug conjugate targeting alkaline phosphatases ALPP and ALPPL2 in solid tumors Yujun Huang, Xiao Liang, Yajuan Xue
• 4402 · PDF 基于EGFR和LGR5双靶向抗体-药物偶联物的治疗策略以改善结直肠癌治疗 EGFR and LGR5 dual-targeting antibody-drug conjugate-based therapeutic strategies for the improved treatment of colorectal cancer Peyton C. High, Zhengdong Liang, Maya Cappellino, Tiffani Blackburn, Cara Guernsey-Biddle, Shraddha Subramanian, Yueh-Ming Shyu, Adela Aldana, Yukimatsu Toh, Kendra S. Carmon
• 4403 · PDF 一种快速稳健的开发流程，提供新型高度内化的抗hHER2抗体-药物偶联物 A fast and robust development process providing new highly internalized anti-hHER2 antibody-drug conjugates Eric Chabrol, Marie-Claire Phélipot, Cécile Lemoigne, Julie Lichière, Nadjiba Marès, Alice Aymard, Alexandre Bagnolini, Sophie Mesnard, Caroline Huber, Matthieu Tassa, Ester Morgado, Jacques Fieschi
• 4404 4404 靶向多个LGR5表位的多样化VHH抗体用于癌症治疗 Diverse VHH antibodies targeting multiple LGR5 epitopes for cancer therapy Chenrui Xu, Yifan Li, Trang Nguyen, Roger Shek, Longfei Chong, Tek H. Lee, Yuxiang Lang, Li Yi, Per Greisen
• 4405 · PDF 对HER2靶向抗体-药物偶联物疗法进行实时、无标记评估 Real-time, label-free assessment of HER2-targeted antibody-drug conjugate therapies Danny Flanigan, BEN STREETER, STACIE CHVATAL, DANIEL MILLARD
• 4406 · PDF micvotabart pelidotin（一种靶向纤连蛋白额外结构域B的抗体偶联药物）的小鼠类似物在免疫治疗难治性同基因头颈鳞状细胞癌模型中显示出抗肿瘤疗效 Mouse analog of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin, demonstrates anti-tumor efficacy in an immunotherapy-refractory syngeneic head and neck squamous cell carcinoma model Anthony B. Rodriguez, Amanda Facklam, Justin Trickett, Sara Lewandowski, Matthew Iovino, Chuan Shen, Frank Wang, Nicolas Severe, Marsha Crochiere
• 4407 · PDF 通过临床蛋白酶谱分析和基于结构的计算机模拟，对用于EGFR阳性肿瘤的PSM101 Lock-抗体进行整合设计 Integrative design of PSM101 Lock-antibody for EGFR-positive tumors through clinical protease profiling and structure-based computer simulation Yi-An Cheng, Yun-Chi Lu, Yu-Chi Lee, Chen-Yung Hung
• 4409 · PDF 比较由trastuzumab和人源化OKT3组成的潜在双特异性形式 Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3 Sabrina Mateos, Catherine Bladen, Abbie Hardisty, Emily Blackwood, Holly Guz, Stacey Walker, Stephen Anderson, Michael Fiebig
• 4410 · PDF 靶向ENPP3的双特异性T细胞衔接器前药的发现与开发 The discovery and development of a bispecific T cell engager prodrug targeting ENPP3 Li Chen, Lindi Wang, Yingyu Li, Xin Wang, Yang Xin, Mingzhu Shao, Jiangtao Ning, Ziyu Chen, Cheng Luo, Jingjing Nie, Yue Wu, Tingting Yang, Hai Huang, Miaomiao Song, Yu Liang
• 4411 · PDF 发现不依赖突变的cKit降解双特异性抗体，在GIST临床前模型中抑制肿瘤生长 Discovery of mutation-independent cKit degrading bispecific antibodies that suppress tumor growth in preclinical models of GIST Kenneth Ng, Shruti Yadav, Brianna McIntosh, Andy Goodrich, Hai Tran, Josef Gramespacher, Kimberly Hoi, Sara Yan, Brian Hiller, Adison McLaggan, Zhong Huang, Noah Solomon, John Coan, Jon Sitrin, Shyra Gardai, Ken Flanagan
• 4412 · PDF GI-128的发现与表征：一种作为巨噬细胞衔接器的PD-L1 x LILRB1/2/4双特异性抗体 Discovery and characterization of GI-128: A PD-L1 x LILRB1/2/4 bispecific antibody as a macrophage engager Seong Hun Kim, Eunji Ahn, Min Sang Yoon, Ji Cheol Kim, Hye Jun Park, Wonjae Lee, Hyuckjun Mok, Eun Jin Lee, Jisoo Kim, Young Min Oh, Kook Hwan Kim, Myoung Ho Jang
• 4413 · PDF KRAS扩增创造出可靶向的pMHC抗原，用于T细胞衔接器治疗以克服KRAS抑制剂耐药 KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance Lorenzo Maso, Diamond N. Mensah, Angelina Pizzo, Sergio A. Rodriguez-Aponte, Samantha Sze, Weifeng Liu, Sean T. Toenjes, Paul Da Silva Jardine, Christoph Rader, Lauren E. Stopfer
• 4414 · PDF 一种靶向蛋白酪氨酸激酶7和成纤维细胞活化蛋白α的双特异性抗体偶联药物同时作用于肿瘤细胞和肿瘤微环境 A bispecific antibody-drug conjugate targeting protein tyrosine kinase 7 and fibroblast activation protein alpha simultaneously acts on tumor cells and the tumor microenvironment Yifan Zhan, Shi Chen, Jingen Xu, Xiaofang Chen, Changping Zheng, Xianfei Pan, Shaojie Wang, Simin Xia, Haijia Yu, Yujie Feng, Guoyuan Peng, Huifeng Jia, Xiaopei Cui, Xiangyang Zhu
• 4415 · PDF 基于AI对数百万张IHC图像的分析识别出19对空间高度共表达的蛋白对,助力双特异性抗体开发 AI-powered analysis of millions of IHC images identifies 19 spatially highly co-expressed protein pairs to enable bispecific antibody development Sukjun Kim, Hosik Kim, Biagio Brattoli, Sergio Pereira, Siraj Mahamed Ali
• 4416 · PDF 通过发现肿瘤选择性AND门和OR门双特异性抗体克服癌症中有限的单特异性靶点格局 Overcoming the limited monospecific target landscape in cancer via discovery of tumor selective AND and OR gate bispecifics Daniel Holdbrook, Katherine Vousden, Michael Hunter, Roy Pettipher, Mark Edwards
• 4417 · PDF GS24-B025,一种新型CDH17和CEA双靶向双特异性抗体-药物偶联物,用于治疗结直肠癌 GS24-B025, a novel CDH17- and CEA-directed bispecific antibody-drug conjugate, for the treatment of colorectal cancer Zeng Qi, Fu Li, Liping Shao, Yuting Lu, Chong Ding, Nan Li, Huan Wang, Weiming He, Qiangqiang Deng, Peng Qi, Wenqiang Zhai, Yihui Lin, Xiaozhen Wang, Fanglong Yang, Siqin Wang, Lei Jin, John L. Xu
• 4418 · PDF 靶向ADAM金属肽酶结构域9的潜在同类最佳喜树碱类抗体-药物偶联物的临床前表征 Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9 Rui Liu, Lan Ding, Yushi Chi, Ge Song, Kuichao Qu, Wan-jen Yang, Kun Yan, Jinbo Liu, Huixin Yan, Xiaoling Yuan, Ying Chen, Zhenjian Li, Chen Hu, Jijun Yuan
• 4419 · PDF 开发一种靶向ALPP/ALPPL2、具有强效抗肿瘤活性和优异耐受性的同类首创喜树碱类抗体-药物偶联物 Development of a first-in-class camptothecin-based antibody-drug conjugate targeting ALPP/ALPPL2 with potent antitumor activity and excellent tolerability Rui Liu, Lingli Zhang, Fan Yang, Junjie Zhang, Wan-Jen Yang, Xiaoling Yuan, Jichen Sha, Yushi Chi, Ge Song, Weiguang Qu, Zhiliang Lv, Qian Zou, Huixin Yan, Chen Hu, Jijun Yuan

在会议检索中浏览本分会场